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Abstract
Background: Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection
and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC. As such,
there is a paucity of data to guide treatment after relapse, and patients are treated similarly to those with de novo
metastatic PDAC (mPDAC). We evaluated the patterns of chemotherapy use and over-all survival (OS) in patients
with recurrent PDAC (rPDAC) following curative therapy.
Methods: In this retrospective study, the Indiana University pancreatic cancer database was used to identify
patients with PDAC who underwent curative resection and subsequently developed recurrence. Demographics,
tumor and treatment characteristics were collected. Patients were broadly divided into those who received
chemotherapy for rPDAC and those who did not. Patients in the former category were further subdivided into
those who received single agent therapy, any standard combination therapy (5-fluorouracil/irinotecan/oxaliplatin
combination or gemcitabine/nab-paclitaxel) and those who received non-standard combinations. Survival analysis
was performed by the Kaplan-Meier method. Log rank tests were used to determine differences in survival between
treated rPDAC patients and those not treated. Cox regression analysis was employed to evaluate factors associated
with OS.
Results: We identified 435 patients with resected PDAC treated between 2008 and 2014. Two hundred and twenty-
three patients (51.2%) were diagnosed with rPDAC. Of these, 140 patients (63%) received chemotherapy whereas 71
patients (32%) did not receive chemotherapy. The 74 patients (53%) who received any standard, approved
multiagent combination regimen had a median OS of 14 months compared to 8 months for the 47 patents (34%)
who received other non-standard combinations and the 19 (13%) who received single agent therapy (P = 0.029).
Multivariate cox regression analysis showed that margin negative resection, peri-operative therapy, radiotherapy
and the use of any chemotherapy for rPDAC were associated with improved OS.
Conclusion: Our findings support the use of standard approved multi-agent therapy in rPDAC. Patients derive
significant benefit from these standard combination therapies with median OS that is comparable to what is
observed with treatment for de novo mPDAC.
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Background
The OS of patients with PDAC has slowly improved
from the often quoted 5 to 8.3% recently [1] . Neverthe-
less, PDAC remains the 4th leading cause of cancer re-
lated death in the United States and is projected to
become the second leading cause within a decade [2, 3].
Among the 10–20% of patients who present with resect-
able disease, adjuvant therapy with fluorouracil or gem-
citabine doubles the surgical cure rate [4, 5] and more
recently, the addition of capecitabine to gemcitabine led
to a 5-year survival of nearly 30% [6]. In spite of these
improvements, up to 80% of patients with rPDAC who
receive curative intent therapy will relapse with local
and/or distant disease, which would be associated with
mortality within 2 years from diagnosis [7, 8].
In the pivotal randomized phase III studies that estab-
lished combination regimens for metastatic PDAC, only
a few patents had rPDAC [9–11]. For instance, in the
MPACT study of gemcitabine and nab-paclitaxel (GnP),
only 7% of enrollees had previously received a Whipple
procedure and 4% received adjuvant therapy. In the AC-
CORD trial, the authors did not specify that percentage
although 5 and 8% in the gemcitabine and FOLFIRINOX
arms respectively had metachronous metastasis. While it
is standard at this time to treat rPDAC similarly to de
novo mPDAC, there are few data regarding outcomes
using combination chemotherapy in rPDAC. The con-
cerns about the tolerability of these regimens have been
documented [12] and these may be amplified in patients
who have recently undergone a pancreaticoduodenect-
omy [13]. Furthermore, it is not clear whether these pa-
tients obtain similar benefit from chemotherapy as
patients with de novo mPDAC.
The objective of this study was to describe the outcome
of patients with rPDAC who received single-agent and
combination chemotherapy regimens after recurrence.
Methods
Study design and population
We conducted a retrospective study using Indiana Uni-
versity’s Institution Review Board (IRB) approved data-
base of patients with PDAC [14]. Information in this
database are gathered retrospectively on an ongoing
basis and stored in the OnCore™ Enterprise Research
System, in compliance with institutional guidelines. Data
are collected from patients’ electronic medical records
(EMR) including clinic visits, radiology and pathology
reports. The current study was approved by the Indiana
University’s IRB. All patients included in the study had
resected PDAC and subsequently developed recurrent dis-
ease (local, distant or both). Patients with rPDAC without
adequate follow-up information or treatment data after re-
currence were excluded from the final analysis.
Data collection
Data on patients with resected PDAC who received any
care (medical, surgical and/ or second opinion evaluation)
between 2008 and 2014 at the Indiana University Simon
Cancer Center gastrointestinal oncology clinics were re-
trieved from the OnCore™ data repository. Demographic
information, tumor and treatment characteristics were
collected and confirmed by an independent review of the
patients’ EMR. The data collected included; age at diagno-
sis, gender, ethnicity, and co-morbid conditions (including
diabetes and other cardiovascular disease). Perioperative
therapy and treatments offered following recurrence were
also recorded. Tumor characteristics such as anatomic lo-
cation, tumor stage, resection margin status and the pres-
ence of lymphovascular and perineural invasion, were
collected. PDAC recurrence was defined by the treating
physician based on a combination of clinical symptoms,
rising CA 19–9 titers and/or radiographic progression
(whether local, distant or a combination of both) while pa-
tients received standard of care routine follow-up.
The type of chemotherapy received for rPDAC was
broadly categorized into single agent therapy, standard
combination with either gemcitabine and nab-paclitaxel
(GnP) or FOLFIRINOX and other non-standard combi-
nations (such as FOLFOX). Because patients may have
received multiple lines of therapy, we defined a line of
therapy as administration of a single active agent or
combination therapy as described above. The addition of
an active agent to a prior single agent or combination
regimen or a switch to a different single agent/combin-
ation constituted a change in line of therapy while dis-
continuation of an agent from a combination did not
qualify as a change in therapy.
This definition was adopted prior to data analysis and
is an adaptation of the definition of the lines of therapy
reported in the metastatic colorectal cancer literature
[15]. Patients who received both a standard and
non-standard combination among their lines of therapy
were categorized for analysis as receiving standard ther-
apy. Data used for analysis were reviewed and are
current till the 31st of March 2017.
Study objectives
The primary objective of this study was to estimate the
OS for patients with rPDAC who received chemotherapy.
We determined OS for those who received single agent,
standard and non-standard combination regimens. The
OS was defined as the time from institution of chemother-
apy following disease recurrence to the date of death or
last follow up. All subsequent references to OS describe a
post recurrence survival period unless otherwise stated.
We also sought to determine the patterns of use of com-
bination chemotherapy for rPDAC patients.
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Statistical analysis
Demographic and clinical characteristics were summarized
and compared between patients who received and did not
receive chemotherapy for rPDAC. Log-rank tests were used
to examine the difference in OS between the different
chemotherapy groups, and Kaplan-Meier estimates of OS
were plotted. Univariate Cox proportional hazard regres-
sion models were used to determine factors associated with
OS. Variables significant at a P-value < 0.25 in the univari-
ate analysis were included in multivariate analysis. All data
were truncated at the date of death, date of last follow up
or the 31st of March 2017, the cutoff date for the analysis.
Data were collected from the OnCore™ Enterprise sys-
tem to a Microsoft Excel spread sheet and analyzed with
the SAS statistics software application v 9.4 (SAS Insti-
tute Inc., Cary, NC).
Results
Patients characteristics
Four hundred thirty-five patients with resected PDAC
were reviewed for this study (Fig. 1). Of these, 223 (51%)
had documented recurrence (rPDAC) and sufficient
follow-up information for final analysis by the data cut-off
date. Of the 223 patients, 140 (63%) patients received sys-
temic chemotherapy, and these constituted the final co-
hort of this study. Fifty-six percent of these were male,
and the median age at diagnosis was 64.3 years. Thirteen
patients (6%) had stage I disease, 13% had stage IIA PDAC
and 80% had Stage IIB disease at the time of diagnosis
(Table 1). The median serum Ca 19–9 at the time of re-
currence was 332.5 U/ml (range (0–140,000 U/ml). Sixty
patients (27%) had local recurrence only and 162 (73%)
had distant recurrence. The median time from diagnosis
to recurrence was 11months (95% CI 10–11months).
In addition, 61 patients (27%) with rPDAC recurred
within 6 months of surgery for primary disease, which
covers the usual period during which adjuvant therapy is
delivered. Forty-one of these patients with early recur-
rence had margin negative resection but 49 had tumor
samples with lymphovascular invasion.
Treatments
Following recurrence, 140 of the 223 patients (63%) re-
ceived systemic. Nineteen (13%) received single agent
therapy only, 74 (53%) received standard combination
treatment and 47 (34%) received only non-standard com-
binations. Seventy-three (52%) patients received only one
line of therapy and 67 (48%) received 2 or more lines of
therapy (Table 2). Based on univariate logistic regression
(with a P value set at < 0.25); female gender, lymphovascu-
lar invasion, presence of local recurrence and periopera-
tive chemotherapy were associated with a lack of
administration of systemic therapy at the time of recur-
rence. Following multivariate modeling of these variables,
only female gender remained significantly associated (OR
1.95, 95% CI, 1.02–3.70, P = 0.00418) with a lack of
chemotherapy administration for rPDAC (Additional file 1:
Table S1 and Table S2).
Fig. 1 Flow chart showing the study population. Four hundred and thirty-five patients were identified from the database of patients with localized
and resected pancreatic cancer. Of the 223 with recurrent pancreatic ductal adenocarcinoma, 140 received systemic hemotherapy and 71 did not
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Table 1 Baseline characteristics of patients with recurrent pancreatic ductal adenocarcinoma
Characteristic *Overall N = 211 No Therapy N = 71 Non-Standard
Combination N = 47
Single Agent N = 19 Standard Combination
N = 74
P-value
Age at diagnosis (years)
Median (range)
64.3 (57.2, 70.6) 67.9 (36.4, 87.2) 64.2 (45.7, 82.7) 64.6 (44.2, 88.9) 61.7 (31.6, 83.9) .00791
Gender .0675
F 96 (45%) 38 (54%) 19 (40%) 12 (63%) 27 (36%)
M 115 (55%) 33 (46%) 28 (60%) 7 (37%) 47 (64%)
Race .7211
Asian 1 (0%) 0 0 0 1 (1%)
Black or African American 9 (4%) 3 (4%) 1 (2%) 2 (11%) 3 (4%)
Other 1 (0%) 1 (1%) 0 0 0
White 200 (95%) 67 (94%) 46 (98%) 17 (89%) 70 (95%)
Stage .0293
I 12 (6%) 2 (3%) 4 (9%) 2 (11%) 4 (6%)
IIA 27 (13%) 6 (8%) 6 (13%) 3 (16%) 12 (17%)
IIB 166 (80%) 63 (89%) 36 (78%) 12 (63%) 55 (76%)
III 3 (1%) 0 0 2 (11%) 1 (1%)
Comorbid Conditions .6393
No 133 (63%) 43 (61%) 32 (68%) 10 (53%) 48 (65%)
Yes 78 (37%) 28 (39%) 15 (32%) 9 (47%) 26 (35%)
Diabetes .3180
No 131 (62%) 41 (58%) 28 (60%) 10 (53%) 52 (70%)
Yes 80 (38%) 30 (42%) 19 (40%) 9 (47%) 22 (30%)
Tumor Location .7085
Body 10 (5%) 3 (4%) 2 (4%) 2 (11%) 3 (4%)
Head 153 (73%) 54 (76%) 37 (79%) 14 (74%) 48 (65%)
Neck 14 (7%) 4 (6%) 1 (2%) 1 (5%) 8 (11%)
Tail 25 (12%) 8 (11%) 4 (9%) 2 (11%) 11 (15%)
Uncinate Process 9 (4%) 2 (3%) 3 (6%) 4 (5%)
Margin Negative Resection .8253
No 51 (24%) 18 (26%) 12 (26%) 3 (16%) 18 (24%)
Yes 158 (76%) 52 (74%) 34 (74%) 16 (84%) 56 (76%)
Lymphovascular Invasion .1892
No 67 (33%) 18 (26%) 13 (30%) 5 (26%) 31 (42%)
Yes 139 (67%) 51 (74%) 31 (70%) 14 (74%) 43 (58%)
Perineural Invasion .9466
No 29 (14%) 9 (13%) 7 (15%) 2 (11%) 11 (15%)
Yes 180 (86%) 61 (87%) 39 (85%) 17 (89%) 63 (85%)
Recurrence Site .8993
Distant 154 (73%) 51 (72%) 36 (77%) 13 (68%) 54 (74%)
Local 56 (27%) 20 (28%) 11 (23%) 6 (32%) 19 (26%)
Perioperative Chemotherapy .0088
No 41 (19%) 21 (30%) 2 (4%) 4 (21%) 14 (19%)
Yes 170 (81%) 50 (70%) 45 (96%) 15 (79%) 60 (81%)
Radiotherapy for rPDAC .8576
No 183 (89%) 61 (87%) 41 (89%) 15 (94%) 66 (90%)
Yes 22 (11%) 9 (13%) 5 (11%) 1 (6%) 7 (10%)
rPDAC: recurrent pancreatic ductal adenocarcinoma. N: number
*Perioperative chemotherapy: combination of patients who received neoadjuvant or adjuvant chemotherapy
1P-value calculated with the ANOVA test
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Radiation therapy was infrequently used in this cohort.
Although 60 patients with rPDAC had local recurrence,
only 11 patients (18%) received radiation therapy, mean
radiation 5080Gy. Another 11 (7%) with distant meta-
static recurrence received radiation (mean 3050Gy). Fo-
cusing on the 140 patients who received systemic therapy,
local recurrence was reported in 36 patients, only 7 of
these received radiation, median dose 5040Gy (range
5000-5040Gy). Six patients with distant metastasis re-
ceived radiation (median 3375Gy, range 2400 – 6000Gy).
Survival outcomes and associated factors
The median post-recurrence OS (mOS) for all patients
with rPDAC was 7 months (95% CI, 6–9 months). Com-
pared with a mOS of 3 months (95% CI 2–4 months) for
patients who did not receive any chemotherapy, patients
who received chemotherapy had a mOS of 10 months
(95% CI 8–13months, P < 0.0001) (Fig. 2). Administra-
tion of standard combination therapy regimens was as-
sociated with a significant improvement in OS
compared to single agent and non-standard combination
chemotherapies (median OS 14months [95% CI 9–17]
versus 8 months [95% CI 6–12months] versus 8 months
[95% CI 5–12months], P = 0.029; Fig. 3). Median OS did
not significantly differ between the cohort that received
perioperative therapy (8months, 95% CI 6–9months) and
those who did not (5months, 95% CI 3–10months), P =
0.2206. (Fig. 4). Furthermore, of the 140 patients who re-
ceived chemotherapy, there was no difference in OS be-
tween those with distant recurrence (N = 103) and the 36
with local recurrence; mOS 10months (95% CI, 7–12
months) vs 12months (95% CI, 8–17months) P = 0.4092.
Table 3 lists factors associated with improved overall
survival in univariate analysis, and multivariate Cox re-
gression of these variables (Table 4) showed that margin
negative resection, perioperative therapy, radiation ther-
apy and chemotherapy for rPDAC were associated with
improved post recurrence survival.
Discussion
There is a scarcity of literature on the utilization of
chemotherapy among patients with rPDAC after initial
curative therapy, and it is not clear the extent to which
prior therapy may affect the ability to deliver subsequent
chemotherapy. After recurrence of PDAC, only 63% of
patients (N = 140) in our cohort received chemotherapy,
and of those, 13% received only single-agent therapy.
The use of more recent, standard combination therapy
Table 2 Treatment administered to patients with recurrent
pancreatic ductal adenocarcinoma
Characteristics Number = 140 (%)
Chemotherapy for rPDAC
Single Agent 19 (13)
Non-Standard Combination 47 (34)
Standard Combination 74 (53)
Lines of chemotherapy for rPDAC
1 73 (52)
2 47 (34)
3 15 (11)
4–6 5 (3)
rPDAC: recurrent pancreatic ductal adenocarcinoma
Fig. 2 Overall Survival analysis of rPDAC patients who received chemotherapy compared to those who did not. The median OS for those who
received chemotherapy (broken lines) was 10 months compared to 3 months without chemotherapy (solid line). Log—rank p < 0.0001
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was associated with longer survival than single-agent or
non-standard combination therapy.
An analysis of the SEER database re-iterated the dismal
outcomes of mPDAC reporting a mOS of only 2months.
There was an improvement in survival for patients youn-
ger than 50 years, and those who were diagnosed in the
later period of the study between 2009 and 2013, which
may reflect the utilization of multi-agent systemic therapy
[16]. Our study, which included a number of patients
treated between 2011 and 2014, coincident with the in-
creased utilization of GnP and FOLFIRINOX is in keeping
with this hypothesis.
Fig. 3 Overall Survival Analysis of rPDAC patients who received different chemotherapy regimens. Patients who received standard combination;
FOLFIRINOX and /or gemcitabine- nab-paclitaxel (tiny broken lines) compared to those who received other non-standard combinations (larger
broken lines) and single agent therapy (solid line). The median OS; standard combinations was 14 months, non-standard and single agent
therapy, 8 months. Log-rank p = 0.0295
Fig. 4 Overall survival analysis of rPDAC patients who received *peri-operative chemotherapy compared to no peri-operative therapy. The
median OS for patients who received peri-operative chemotherapy (broken line) was 8 months and 5months for those who did not receive
perioperative chemotherapy (solid line). Log—rank p < 0.2206. *perioperative (both adjuvant and neoadjuvant therapy)
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In another study conducted prior to the GnP and
FOLFIRINOX era, Meyers and colleagues reported that
single agent chemotherapy was administered to 45 of 70
patients with rPDAC (64%) [17]. With a mOS of 10
months, the patients who received therapy seemed to do
at least as well as those with de novo mPDAC treated
with single agent therapy. A Japanese group also re-
ported outcomes for single agent gemcitabine in recur-
rent versus de novo metastatic PDAC patients. In their
series, recurrent patients (who were never previously ex-
posed to gemcitabine) had longer survival on gemcita-
bine than did de novo metastatic patients [18]. It is
likely that there was a higher prevalence of patients with
poor functional status in the de novo metastatic group.
Another retrospective review of 40 patients treated in
the ‘modern’ era reported a median OS of 16.6 months
with chemotherapy for rPDAC. Although numerically
superior, it was not statistically different from a median
OS of 9.7 months among 141 patients with de novo
mPDAC. Of note, only 33% of the rPDAC and 50% of
the mPDAC cohort received combination chemotherapy.
The treatment regimens employed in this review were
FOLFIRINOX, GnP and Gemcitabine and S1 [19].
Our study adds to the literature in several ways. We
demonstrate that a significant proportion of patients
treated for rPDAC are able to receive multi-agent
Table 3 Univariate analysis of factors associated with overall survival
Factor Comparison Hazard Ratio Lower 95%CL Upper 95%CL P-value
Gender F vs. M 1.02 0.77 1.36 0.8857
Pathologic Stage IIA vs. I 1.08 0.51 2.32 0.8368
IIB vs. I 1.77 0.93 3.37 0.0805
Chemotherapy for rPDAC Yes vs. No 0.31 0.23 0.43 <.0001
Margin Negative Yes vs. No 0.75 0.54 1.04 0.0860
Lymphovascular Invasion Yes vs. No 1.53 1.11 2.10 0.0089
Perineural Invasion Yes vs. No 0.97 0.64 1.46 0.8731
Co-morbid Conditions Yes vs. No 1.11 0.83 1.50 0.4805
Diabetes Mellitus Yes vs. No 0.90 0.67 1.22 0.5040
Radiotherapy for rPDAC Yes vs. No 0.57 0.35 0.92 0.0207
Recurrence site Distant vs. Local 1.15 0.83 1.59 0.3979
aPerioperative therapy Yes vs. No 0.80 0.56 1.14 0.2220
rPDAC chemotherapy group Non-Standard Combination vs. Single Agent 0.82 0.47 1.43 0.4764
rPDAC chemotherapy group Standard Combination vs. Single Agent 0.54 0.31 0.92 0.0246
Ca19–9 at recurrence <1000 U/ml vs >1000 U/ml 1.007 0.999 1.016 0.0914
CA19–9 at diagnosis <1000 U/ml vs >1000 U/ml 1.073 1.038 1.108 <.0001
rPDAC recurrent pancreatic ductal adenocarcinoma
aPerioperative therapy: combination of patients who received neoadjuvant or adjuvant therapy
Table 4 Multivariate Cox Regression Model of factors associated with overall survivala
Factor Comparison Hazard Ratio Lower 95%CL Upper 95%CL P-value
Pathologic Stage IIA vs. I 0.52 0.19 1.40 0.1953
IIB vs. I 1.70 0.75 3.87 0.2067
III vs. I 1.19 0.23 6.15 0.8378
Chemotherapy for rPDAC Yes vs. No 0.14 0.08 0.24 <.0001
Margin negative resection Yes vs. No 0.57 0.35 0.93 0.0245
Lymphovascular invasion Yes vs. No 1.15 0.69 1.92 0.5937
Radiotherapy for rPDAC Yes vs. No 0.28 0.14 0.53 <.0001
Perioperative therapy Yes vs. No 1.81 1.02 3.22 0.0417
Ca19–9 level at recurrence Above 1000 U/ml 1.012 1.002 1.023 0.0237
CA19–9 level at diagnosis Above 1000 U/ml 1.066 1.014 1.122 0.0131
Variables with P value < 0.25 from univariate analysis were included in this model
aPerioperative therapy: combination of patients who received neoadjuvant or adjuvant therapy
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combination regimens. We also show that the mOS ob-
tained with the approved combinations of FOLFIRINOX
or GnP (14months) is comparable to mOS with these
combinations for de novo mPDAC. Additionally, patients
seem to derive benefit from chemotherapy at the time of
recurrence irrespective of prior perioperative therapy. To
date, this is the largest dataset documenting the utilization
of modern combination regimens for rPDAC.
Several limitations exist in our study. The retrospective
nature of the study meant that potentially important data
points were not collected. For example, information on per-
formance status was recorded in only a handful of patients.
Given that functional status is an important consideration
for offering single agent compared to multiagent therapy,
we are unable to exclude selection bias as a significant con-
tributor to the superior outcomes with standard combin-
ation chemotherapy agents. Additionally, the reason for not
receiving therapy at the time of relapse was not recorded.
We therefore were unable to investigate the potential roles
of a number of factors including; morbidity from surgical
resection and adjuvant therapy, short disease-free interval,
rapid progression, comorbidities or patients’ decision on
failure to receive therapy. The effect of a favorable/less
aggressive disease biology in determining overall survival
can therefore not be ruled out. These important questions
should be addressed in a prospective manner.
Only 19 patients received single agent chemotherapy in
this study and it is difficult to draw strong conclusions
from such low numbers. However, double this number re-
ceived non-standard combination regimens and OS was
significantly inferior in this group compared to standard
chemotherapy agents. This makes a compelling case for
using standard regimens in recurrent PDAC patients con-
sidered for combination chemotherapy.
Conclusion
To our knowledge, this is the largest study describing
the outcomes of patients with rPDAC following curative
therapy. Our data demonstrate that more than half of
patients with rPDAC receive multiagent chemotherapy
regimens. The survival outcome reported with modern
standard chemotherapy combinations in this study is
similar to the outcome with similar regimens in meta-
static PDAC. This, therefore, supports the current clin-
ical practice of treating patients with recurrent PDAC
similar to those with de novo metastatic disease and
provides rationale for inclusion of more of these patients
in ‘first line’ clinical trials for metastatic PDAC.
Additional file
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regression of factors associated with not using chemotherapy for rPDAC
Factors significant at a P value <0.25 on univariate analysis were utilized in
the multivariate analysis (DOCX 15 kb)
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